EKF Diagnostics Holdings PLC Directorate Change (1143E)
28 Juni 2023 - 8:00AM
UK Regulatory
TIDMEKF
RNS Number : 1143E
EKF Diagnostics Holdings PLC
28 June 2023
This announcement contains inside information
for the purposes of UK Market Abuse Regulation.
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Directorate Change
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global
diagnostics business, announces that Marc Davies is standing down
from his role as Chief Financial Officer ("CFO") to pursue other
opportunities. Marc will remain in his position to facilitate an
orderly handover to his replacement for up to six months, as
required.
The Company is already in advanced discussions with a suitable
candidate for the CFO role, who is experienced in working with
AIM-quoted healthcare companies, and is be able to commence the
handover process within the next few weeks, with a view to taking
on the role permanently in Q4 2023. A further announcement relating
to this appointment will be made in due course.
Julian Baines remains Executive Chair and is committed to
executing the Company's growth strategy, whilst also overseeing the
recruitment process for a new Chief Executive Officer. An
experienced senior management team continues to support the
Executive Chair on an operational level, alongside significant
strategic input from the Non-executive Directors.
Julian Baines, Executive Chair of EKF, commented: "I would like
to thank Marc for his contribution to the Company. We remain
confident in the financial condition and robustness of our business
and the potential value that EKF offers to shareholders. We have a
well-established and growing core business in Point-of Care, and an
exciting opportunity in our Life Sciences division over the coming
years ."
The Company expects to give its next scheduled update on H1
trading in late July.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Julian Baines, Executive Chair Tel: +44 (0)29 2071 0570
Singer Capital Markets (Nominated Adviser & Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / George Tzimas / Oliver
Platts
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584 391
303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is an AIM-listed global diagnostics business focussed
on:
-- Point-of-Care analysers in the key areas of Hematology and
Diabetes, as well as Central Laboratory products including clinical
chemistry reagents, analysers and centrifuges
-- Life Sciences services provide specialist manufacture of
enzymes and custom products for use in diagnostic, food and
industrial applications, as well as other higher value Contract
Manufacturing services
EKF has headquarters in Penarth (near Cardiff) and operates five
manufacturing sites across the US and Germany, selling into over
120 countries world-wide.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUUCQUPWGRM
(END) Dow Jones Newswires
June 28, 2023 02:00 ET (06:00 GMT)
EKF Diagnostics (AQSE:EKF.GB)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
EKF Diagnostics (AQSE:EKF.GB)
Historical Stock Chart
Von Dez 2023 bis Dez 2024